Reimbursement, not approval, is the commercial gate, and leaders should plan accordingly
This month's payer decisions from CMS, China's NRDL and Medicare show that price and access are set by policy calendars. Companies that treat them as afterthoughts will pay for it.
The payer writes the revenue line
Regulatory approval says a product may be sold. A reimbursement decision says whether anyone will be paid for using it, and at what price. In the past few days, three unrelated companies have shown which of the two controls the commercial story.
Our position is simple. In pharma and its adjacent sectors, payment decisions are the most consequential events in a product's life, and companies should manage them with the same rigour they bring to a regulatory submission.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Show your working: launch revenue is the lagging indicator, and this season proves it
Headline growth rates from small launches are easy to produce and hard to compare. The results that persuade pair revenue with evidence of demand and a plan the economics can fund.
Gross margin is the number that turns a launch into a business
Revenue growth was easy to find in this earnings season. The companies that pair it with unit economics, as Delcath and Autolus have begun to, are the ones that will set their own terms.
The first launch is a down payment: this earnings season rewards the label that funds the next one
Kura, Autolus, ADC Therapeutics and others are using first-product revenue to underwrite a second act. The risk is trying to do both at once.